ArticleBlood2021
Development of CAR T-cell lymphoma in 2 of 10 patients effectively treated with piggyBac-modified CD19 CAR T cells.
Open access · bronzeAbstract readClinical Trial, Phase ILetter
In one paragraph
Article in Blood, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 117 papers.
0numbers the graph read from it
0cells of the map it votes in
117citing papers in PubMed
11.4field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
117 citing papers in PubMed, 165 citations in OpenAlex.
- A review of genetic modification for ex vivo cellular therapies.Transfusion · 2026Article
- T cell lymphomas: cancers of aberrant immune synapse signalling.Nature reviews. Immunology · 2026Review
- Genomic features of clonal hematopoiesis-associated genes in primary and CAR T-cell-related secondary T-cell malignancies.Blood neoplasia · 2026Article
- CAR-NK cell therapy for hematological malignancies.Blood advances · 2026Review
- Review
- CRISPR-Cas9 engineering of CAR-T cells: Can non-viral nanoparticles unlock safer and scalable genome editing?iScience · 2026Review
- Secondary malignancy of T-cell origin after CAR T-cell therapy: EMA's conclusions from the evaluation of 38 suspected cases.Gene therapy · 2026Article
- Biomarker-empowered precision navigation of CAR-T cell therapy.Molecular cancer · 2026Review
- Beyond CAR-T and oncology: broadening chimeric antigen receptor technologies across cell types and diseases.Precision clinical medicine · 2026Review
- A precision gene-engineered B cell medicine producing sustained levels of active factor IX for hemophilia B therapy.Molecular therapy : the journal of the American Society of Gene Therapy · 2026Article
- Secondary Malignancies of Chimeric Antigen Receptor T-cell Therapy: A Multidimensional Analysis of Mechanisms, Risk Factors, and Treatment Strategies.Anti-cancer agents in medicinal chemistry · 2026Review
- Development andFrontiers in immunology · 2026Article
- Review
- Unveiling genomic rearrangements in engineered iPSC lines by optical genome mapping.Molecular therapy. Methods & clinical development · 2025Article
- Peripheral T cell lymphoma following CD19-targeted chimeric antigen receptor T cell therapy.International journal of hematology · 2025Article
- Natural killer cells in adoptive cell therapy: current landscape of genetic engineering strategies.Oncoimmunology · 2025Review
- Use of a Foamy-Virus Vector System to Produce an 'Off-the-Shelf' Fcγ-CR-T Cell Product for the Treatment of Haematological and Solid Tumour Malignancies.Immunology · 2025Article
- Preventing secondary primary malignancies (SPMs) in CAR-T cell therapy through site-specific transgene integration into genomic safe harbors (GSHs).Journal of translational medicine · 2025Review
- Fine tuning towards the next generation of engineered T cells.Nature biomedical engineering · 2025Review
- [Frontier advances in chimeric antigen receptor T cells and chimeric antigen receptor regulatory T cells therapies for autoimmune diseases].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2025Review
57 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
23 authors at 5 institutions in 1 country.
David C BishopWestmead Institute for Medical Research, Sydney, NSW, Australia.ORCID 0000-0001-6415-1455
Leighton E ClancyWestmead Institute for Medical Research, Sydney, NSW, Australia.
Renee SimmsWestmead Institute for Medical Research, Sydney, NSW, Australia.
Jane BurgessWestmead Institute for Medical Research, Sydney, NSW, Australia.
Geetha MathewWestmead Institute for Medical Research, Sydney, NSW, Australia.ORCID 0000-0002-2154-2672
Leili MoezziWestmead Institute for Medical Research, Sydney, NSW, Australia.
Janine A StreetWestmead Institute for Medical Research, Sydney, NSW, Australia.
Gaurav SutraveWestmead Institute for Medical Research, Sydney, NSW, Australia.
Elissa AtkinsDepartment of Haematology , Westmead Hospital, Sydney, NSW, Australia.
Helen M McGuireRamaciotti Facility for Human Systems Biology, University of Sydney, Sydney, NSW, Australia.ORCID 0000-0003-2047-6543
Brian S GlossWestmead Institute for Medical Research, Sydney, NSW, Australia.
Koon LeeWestmead Institute for Medical Research, Sydney, NSW, Australia.ORCID 0000-0001-9541-3876
Wei JiangWestmead Institute for Medical Research, Sydney, NSW, Australia.ORCID 0000-0002-1049-7239
Karen MaddockDepartment of Haematology , Westmead Hospital, Sydney, NSW, Australia.
Georgia McCaughanSydney Medical School, Faculty of Medicine and Health, University of Sydney, Sydney, NSW, Australia.ORCID 0000-0002-4838-9022
Selmir AvdicWestmead Institute for Medical Research, Sydney, NSW, Australia.
Vicki AntonenasBlood Transplant and Cell Therapies Laboratory, NSW Health Pathology-ICPMR Westmead, Sydney, NSW, Australia.
Tracey A O'BrienChildren's Cancer Institute, Sydney, NSW, Australia.
Peter J ShawBMT Services, Children's Hospital at Westmead, Sydney, NSW, Australia.ORCID 0000-0003-0101-4482
David O IrvingAustralian Red Cross Lifeblood, Sydney, NSW, Australia; and.ORCID 0000-0003-2434-0686
David J GottliebWestmead Institute for Medical Research, Sydney, NSW, Australia.
Emily BlythWestmead Institute for Medical Research, Sydney, NSW, Australia.ORCID 0000-0002-7849-7139
Kenneth P MicklethwaiteWestmead Institute for Medical Research, Sydney, NSW, Australia.
The University of Sydney · AUWestmead Institute for Medical Research · AUWestmead Hospital · AUUniversity of Technology Sydney · AUUNSW Sydney · AU
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
AdultAgedDNA Transposable ElementsFemaleHematopoietic Stem Cell TransplantationHumansImmunotherapy, AdoptiveLeukemia, B-CellLymphomaLymphoma, B-CellMaleMiddle AgedReceptors, Antigen, T-CellTreatment OutcomeYoung AdultCD19-specific chimeric antigen receptorDNA Transposable ElementsReceptors, Antigen, T-Cell
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.